Valuation : Gain Therapeutics, Inc.

Market Cap 79.43M 68.35M 64.31M 58.75M 110M 7.5B 110M 760M 295M 3.85B 298M 292M 12.4B P/E 2026 *
-3.73x
P/E 2027 * -2.79x
Enterprise Value 79.43M 68.35M 64.31M 58.75M 110M 7.5B 110M 760M 295M 3.85B 298M 292M 12.4B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.77%
Yield 2026 *
-
Yield 2027 * -
1 day-0.82%
1 week+2.54%
Current month+0.83%
1 month+3.12%
3 months-2.42%
6 months-29.38%
Current year-43.63%
1 week 1.75
Extreme 1.75
1.85
1 month 1.73
Extreme 1.73
2.37
Current year 1.53
Extreme 1.53
3.29
1 year 1.53
Extreme 1.53
4.34
3 years 0.89
Extreme 0.89
5.33
5 years 0.89
Extreme 0.89
9.75
10 years 0.89
Extreme 0.89
17.93
Manager TitleAgeSince
Chief Executive Officer 52 24/06/2024
Director of Finance/CFO 37 05/01/2025
Chief Tech/Sci/R&D Officer - 24/03/2024
Director TitleAgeSince
Chairman 69 31/12/2016
Director/Board Member 63 30/04/2019
Director/Board Member 58 31/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Free

Director

25,000 0.0586%
15/07/26 Free

Founder

25,000 0.0586%
15/07/26 Free

Director

25,000 0.0586%
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%+2.54%+4.31%-45.50% 79.43M
-2.54%-2.84%-1.90%+14.52% 50.35B
-0.96%+0.77%+437.81%+521.78% 45.2B
-1.59%+2.36%+45.55%+21.29% 44.71B
-1.12%-2.20%+12.53%+75.10% 41.24B
+0.53%-1.67%+15.16%+49.88% 33.08B
-0.46%+8.37% - - 17.81B
-0.12%-1.30%+22.91%+123.64% 16.56B
-1.01%+0.50%+15.83%+27.98% 14.82B
-1.41%-0.91%+77.97%+41.40% 14B
Average -0.96%-0.15%+70.02%+92.23% 27.78B
Weighted average by Cap. -1.16%-0.46%+94.04%+127.10%

Financials

2026 *2027 *
Net sales - -
Net income -21.57M -18.56M -17.46M -15.95M -29.84M -2.04B -29.92M -206M -80.06M -1.04B -80.98M -79.22M -3.37B -33.2M -28.57M -26.88M -24.56M -45.94M -3.13B -46.06M -318M -123M -1.61B -125M -122M -5.18B
Net Debt - -
Logo Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Employees
-
Date Price Change Volume
04/09/26 US$1.815 -0.27% 126,945
03/09/26 US$1.820 +1.68% 391,412
02/09/26 US$1.790 +1.13% 367,689
01/09/26 US$1.770 -1.67% 197,909
31/08/26 US$1.800 +1.69% 259,893
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.820USD
Average target price
7.200USD
Spread / Average Target
+295.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GANX Stock